III.L 0MSFT 0.31GO.U.TO 0.3CIU.PR.A.TO 0DAL -0.02CDZ.TO 0.42NET -0.42KLAC 1.81
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

373.76
-0.39 (0.10%)
as of Jul 2, 2026, 10:54:55 pm Market Open.
106 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 5, 2026, 12:00 am

This summary was created by AI, based on 17 opinions in the last 12 months.

Amgen Inc. (AMGN) is highly regarded among experts for its stable management and well-executed innovative pipeline, featuring 15 products that have demonstrated double-digit revenue growth. Multiple analysts highlight the company's promising GLP-1 weight-loss drug currently in phase 3 testing, pointing to its potential as a game-changer in the market. Despite some concerns about slower growth compared to peers, many see AMGN as a safer investment within the biotech sector, especially given its reasonable forward P/E ratio below 20x and attractive dividend yield, which is around 3.23% to 3.46%. The stock appears to be breaking out to new highs and has recently been upgraded, reinforcing the belief in its upward trajectory as the industry evolves. Overall, AMGN is considered a solid holding for investors looking for exposure to large-cap biotech, particularly with strong earnings potential and an optimistic outlook steering toward 2027.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
GILD
PAST TOP PICK

Amgen Inc.(AMGN)

May 06, 2003
(Was a top pick on Apr 7. Up 7.4%) Still likes.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$60.97

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 30, 2003
Three drugs are coming out which are blockbusters.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$61.30

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 07, 2003
Expects the S&P to drop to 820 and this stock could drop. Buy on pull backs. Has three block buster drugs on the way.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$58.41

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Jan 13, 2003
Very successful biotech. Big growth. May be a little high.
Photo of Neil MurdockNeil MurdockUnlock Rating
$51.52

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Aug 13, 2002
18/20% growth for the next few years. Would prefer to buy in the $30's.
Photo of Andrew McCreathAndrew McCreathUnlock Rating
$45.64

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Amgen Inc.(AMGN)

Jul 03, 2002
The biotech sector is down. A high quality company.
Photo of David BaskinDavid BaskinUnlock Rating
$35.83

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Jan 02, 2002
Doesn't like their run at Immunex.
Photo of Brad WillockBrad WillockUnlock Rating
$56.40

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Dec 28, 2001
A little high now. Would buy at $50.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$59.06

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Dec 19, 2001
Too expensive.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$58.33

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Jul 31, 2001
A good buy and hold. Good products. Volatile.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$62.71

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Jul 06, 2001
Good broad spectrum. Volatile.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$57.16

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Jun 06, 2001
(Was a top pick on Feb 22/01 down 3%)Still likes. A good entry point. Likes better than Hemasol.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$68.20

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Feb 22, 2001
Biotechs should grow substantially. A core company in the biotech sector. Has a pipeline. Profitable.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$70.06

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Jan 08, 2001
Likes. In late stage production
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$58.69

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Oct 30, 2000
Facing risks on patents and drugs not that good.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$54.00

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Showing 151 to 165 of 165 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX 0$77.65
GOOG -0.5$355.68
CAT 1.47$965
NFLX 0$77.65
AAPL -0.2$308.43

Today's Top Picks

III.L 0$2999
MSFT 0.31$390.8
GO.U.TO 0.3$9.55
CIU.PR.A… 0$
DAL -0.02$92.73

Popular Articles

Latest Sell Signals

CAT 1.47$965
ASML 5.87$1775.1899
TRI.TO -1.74$124.88
EIF.TO 2.09$132.94
MU 0.84$976.4

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like